Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature
Crizotinib, an oral first-generation tyrosine kinase inhibitor (TKI), is superior to systemic chemotherapy for the treatment of non-small cell lung cancer (NSCLC) with positive rearrangement of anaplastic lymp...
Source: Diagnostic Pathology - Category: Pathology Authors: Peng Zhang, JiaHua Xu, Qing Wu, Jianxin Qian and Song Wang Tags: Case Report Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Pathology